Physician profile
John W Bailey
NPI 1548203599
$11,862.03
in general payments reported to CMS, 2019-2025
62 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $1,568 · 2021: $2,027 · 2022: $1,510 · 2023: $1,619 · 2024: $2,088 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,580.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.98 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $977.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $880.30 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $860.75 | 2019-2025 | |
| Lilly USA, LLC | $641.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $533.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $499.19 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $473.03 | 2019-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $454.39 | 2019-2024 | Belsomra, Steglatro, Steglujan |
| Abbott Laboratories | $371.74 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $355.89 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.83 | 2019-2024 | Jardiance |
| Corcept Therapeutics | $334.56 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $306.27 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $295.36 | 2019-2024 | Trintellix |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.